China pharma firms turn to local reagent suppliers to cut costs and delivery times

Pharmaceutical companies in China are increasingly turning to local reagent suppliers to reduce costs, delivery times, and uncertainty caused by trade tensions with the U.S. Previously dominated by Western firms like Thermo Fisher and Merck, Chinas reagent market—valued at $5.76 billion in 2024—is seeing a shift toward domestic producers such as Shanghai Titan Scientific and Nanjing Vazyme Biotech.